Even with the relatively small numbers of patients with stage I disease in our cohort, and the confounding effect of adjuvant chemotherapy, our data contribute to the growing body of evidence that small T1 HER2+ cancers may have an inferior outcome compared with small HER2-negative cancers (Joerger et al, 2011). The gene discussed is ERBB2; the disease is cancer.